Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.

Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC.

Value Health. 2007 Sep-Oct;10(5):367-76.

2.
3.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

4.

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.

Lundkvist J, Wilking N, Holmberg S, Jönsson L.

Breast Cancer Res Treat. 2007 May;102(3):289-99. Epub 2006 Oct 11.

PMID:
17033927
5.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

6.

Exemestane: a review of its use in postmenopausal women with breast cancer.

Deeks ED, Scott LJ.

Drugs. 2009;69(7):889-918. doi: 10.2165/00003495-200969070-00007. Review.

PMID:
19441873
7.

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.

Skedgel C, Rayson D, Dewar R, Younis T.

Breast Cancer Res Treat. 2007 Mar;101(3):325-33. Epub 2006 Aug 2.

PMID:
16897433
8.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study..

Lancet. 2007 Feb 17;369(9561):559-70. Erratum in: Lancet. 2007 Mar 17;369(9565):906.

PMID:
17307102
9.
10.

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V.

Clin Breast Cancer. 2007 Jun;7(8):608-18.

PMID:
17592673
11.

To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?

Iddon J, Bundred NJ.

Expert Rev Anticancer Ther. 2008 Jan;8(1):9-13. Review.

PMID:
18095878
13.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

Bertelli G, Hall E, Ireland E, Snowdon CF, Jassem J, Drosik K, Karnicka-Mlodkowska H, Coombes RC, Bliss JM.

Ann Oncol. 2010 Mar;21(3):498-505. doi: 10.1093/annonc/mdp358. Epub 2009 Aug 28.

14.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study..

N Engl J Med. 2004 Mar 11;350(11):1081-92. Erratum in: N Engl J Med. 2004 Dec 2;351(23):2461. N Engl J Med. 2006 Oct 19;355(16):1746. van de Velde, Cornelius [added].

15.

Intergroup Exemestane Study mature analysis: overall survival data.

Jassem J; International Exemestane Study Group..

Anticancer Drugs. 2008 Feb;19 Suppl 1:S3-7. doi: 10.1097/01.cad.0000277608.23376.bc.

PMID:
18340242
16.
17.
18.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
19.

Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.

Erman A, Nugent A, Amir E, Coyte PC.

Breast Cancer Res Treat. 2014 Jun;145(2):267-79. doi: 10.1007/s10549-014-2950-6. Epub 2014 Apr 26.

PMID:
24771048
20.

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.

Breast Cancer. 2007;14(1):81-7. Review.

Supplemental Content

Support Center